Pathophysiologische und experimentelle Grundlagen für die Prophylaxe des plötzlichen Herztodes mit Aggregationshemmern

• LITERATUR

• 1 Ali M., McDonald J. W. D.. Reversible and irreversible inhibition of platelet cyclooxyge-nase and serotonin release by non-steroidal antiinflammatory drugs. Thrombosis Research 1978; 13: 1057
• 2 Andrassy K., Malluche Bornefeld H.. Prevention of p.o. clotting of a.v. cimino fistulae with acetylsalicylic acid. Results of a prospective double blind study. Klin. Wschr. 1974; 52: 348
• 3 Au T. L. S., Collins G. A., Harvie C. J., Walker M. J. A.. The actions of prostaglandins I₂ and E₂ on arrhythmias produced by coronary occlusion in the rat and dog. Prostaglandins 1979; 18: 707
• 4 Buchanan M. R., Rosenfeld J., Hirsh J.. The prolonged effect of sulfinpyrazone on collagen-induced platelet aggregation in vivo. Thrombosis Research 1978; 13: 883
• 5 Buchanan M. R., Dejana E., Gent M., Mustard J. F., Hirsh J.. Enhanced platelet accumulation onto injured carotid arteries in rabbits after aspirin treatment. J. clin. Invest. 1981; 67: 503
• 6 Butler K. D., White A. M.. Inhibition of platelet involvement in the sublethal Forss-man reaction by sulfinpyrazone. In McGregor M., Mustard J. F., Oliver M. F., Sherry S.. (eds.) Cardiovascular actions of sulfinpyrazone: Basic and clinical research. Miami Symposia Specialists, S. 3, 1980
• 7 Cazenave J. P., Packham M. A., Kin-lough-Rathbone R. L., Mustard J. F.. Platelet adherence to the vessel wall and to collagen-coated surfaces. Advances in Experimental Medicine and Biology 1978; 102: 31
• 8 Chandler A. B., Chapman I., Erhardt L. R., Roberts W. C., Schwartz C. J., Sinapius D., Spain D. M., Sherry S., Ness P. M., Simon T. L.. Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Amer. J. Cardiol. 1974; 34: 823
• 9 Collins G. A., Johnston K. M., Martinez T. T., Walker M. J. A.. Prostaglandins have limited actions on abnormalities of beating induced in cultured heart cells. Prostaglandins 1979; 18: 591
• 10 Cortellaro M., Boschetti C., Fassio G., Basagni M., Polli E. E.. A controlled trial of the effect of sulfinpyrazone on platelet survival and on platelet-bound ¹⁴C-serotonin release in patients with previous myocardial infarction. Acta haemat. 1979; 61: 68
• 11 Curwen K. D., Gimbrone M. A., Handin R. I.. In vitro studies of thromboresistance: the role of prostacyclin (PGI₂) in platelet adhesion to cultured normal and virally transformed human vascular endothelial cells. Lab. Invest. 1980; 42: 366
• 12 Davies J. A., Essien E., Cazenave J. P., Kinlough-Rathbone R. L., Gent M., Mustard J. F.. The influence of red blood cells on the effects of aspirin or sulfinpyrazone on platelet adherence to damaged rabbit aorta. Brit. J. Haemat. 1979; 42: 283
• 13 Dejana E., Cazenave J. P., Groves H. M., Kinlough-Rathbone R. L., Richardson M., Packham M. A., Mustard J. F.. The effect of aspirin inhibition of PGI₂ production on platelet adherence to normal and damaged rabbit aorta. Thrombosis Research 1980; 17: 453
• 14 Di Minno G., Villa S., Bertele De Gaetano V.. Dipyridamole as an antithrombotic agent: an intricate mechanism of action. In Noseda G., Lewis B., Paoletti R.. (eds.) Diet and drugs in atherosclerosis. Raven Press; New York: 1980
• 15 Dix R. K., Kelliher G. J., Jurkiewicz N., Lawrence T. H.. The influence of prostacyclin on coronary occlusion-induced arrhythmia in cats. Prostaglandins and Medicine 1979; 3: 173
• 16 Ellis E. F., Wright K. F., Jones P. S., Richardson D. W., Ellis C. K.. Effect of oral aspirin dose on platelet aggregation and vascular prostacyclin (PGI₂) synthesis in humans or rabbits. J. Cardiovascular Pharmacology 1980; 2: 387
• 17 Fields W. S., Lemak N. A., Frankowski R. F., Hardy R. J.. Controlled trial of aspirin in cerebral ischemia. Stroke 5/301 1977
• 18 Folts J. E. D., Crowell E. B., Rowe G. G.. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365
• 19 Folts J. E. D., Rowe G. G.. Platelet aggregation in stenosed coronarles: mechanism of sudden death. Amer. J. Cardiol. 1978; 41: 425
• 20 Forfar J. C , Russell D. C., Oliver M. F.. Acute hemodynamic effects of oral sulfinpyrazone on exercise responses in man. Circulation 1980; 62 III 327 Supplementum
• 21 Friedman M., Manwaring J. H., Rosen-man R. H., Donlon G., Ortega P., Grube S. M.. Instantaneous and sudden deaths. Clinical and pathological differentiation in coronary artery disease. J. Amer. med. Ass. 1973; 225: 1319
• 22 Goldstein R. E., Davenport N. J., Capur-ro N. L., Lipson L. C., Bonow R. O., Shulman N. R., Epstein S. E.. Relative effects of sulfinpyrazone and Ibuprofen on canine platelet function and prostaglandin-mediated coronary vasodilation. J. Cardiovascular Pharmacology 1980; 2: 399
• 23 Gordon J. L., Pearson J. D.. Effects of sulfinpyrazone and aspirin on prostaglandin I₂ (prostacyclin) synthesis by endothelial cells. Brit. J. Pharmacol. 1978; 64: 481
• 24 Haerem J. W.. Platelet aggregates inintramyo-cardial vessels of patients dying suddenly and unexpectedly of coronary artery disease. Atheroslerosis 1972; 15: 199
• 25 Haerem J. W.. Mural platelet microthrombi and major acute lesions of main epicardial arteries in sudden coronary death. Atherosclerosis 1974; 19: 529
• 26 Harker L. A., Ritchie J. L.. The role of platelets in acute vascular events. Circulation 1980; 62 V 13 Supplementum
• 27 Harris W. H., Salzman E. W., Athanasou-lis C. A., Waltmann A. C., De Sanctis R. S.. Aspirin prophylaxis of venous thromboembolism after total hip replacement. New Engl. J. Med. 1977; 297: 1246
• 28 Harter H. R., Burch J. W., Majerus P. W., Stanford N., Delmez J. A., Anderson C. B., Weerts C. A.. Prevention of thrombosis in patients on hemodialysis by low dose aspirin. New Engl. J. Med. 1979; 301: 577
• 29 Jakobsen P., Kistein Pedersen A.. Two metabolites of sulfinpyrazone and their identification and determination by mass specto-metry. J. Pharmaceutical Pharmacology 1981; 33: 89
• 30 Jobin F.. Acetylsalicylic acid. hemostasis, and human thromboembolism. Seminars in Thrombosis and Haemostasis 1978; 4: 199
• 31 Jorgensen L., Rowsell H. C., Hovig T., Glynn M. F., Mustard J. F.. Adenosine diphos-phate-induced platelet aggregation and myocardial infarction in swine. Lab. Invest. 1967; 17: 616
• 32 Jorgensen L.. Pathophysiologische und experimentelle Hinweise auf die Bedeutung der Thrombozyten bei koronarer Herzkrankheit und plötzlichem Herztod. In Abe T., Sherry S.. (eds.) Ein neuer Weg zur Eindämmung des Herztodes. Huber, Bern, Stuttgart, Wien 1979; S. 27
• 33 Kelton J. G., Hirsh J., Carter C. J., Buchanan M. R.. Thrombogenic effect of high-dose aspirin in rabbits: relationship to inhibition of vessel wall synthesis of prostaglandin I₂-like activity. J. Clin. Invest. 1978; 62: 892
• 34 Kinlough-Rathbone R. L., Cazenave J. P., Packham M. A., Mustard J. F.. Effect of inhibition of the arachidonate pathway on the release of granule contents from platelets adherent to collagen. Lab. Invest. 1980; 42: 28
• 35 Kuller D.. Sudden death - definition and epidemiologic considerations. Progr. cardio-vasc. Dis. 1980; 23: 1
• 36 Lewis G. P., Westwick J.. The effect of sulfinpyrazone. sodium aspirin and Oxprenolol on the formation of arterial platelet thrombi. British Journal of Pharmacology 1975; 55: 255P
• 37 Livio M., Villa S., DeGaetano G.. Long-lasting inhibition of platelet prostaglandin but normal vascular prostacyclin generation following sulfinpyrazone administration to rats. J. Pharmaceutical Pharmacology 1980; 32: 718
• 38 Lovegrove T., Thompson P.. The role of acute myocardial infarction in sudden cardiac death - a statisticians' nightmare. Amer. Heart J. 1978; 96: 711
• 39 Maguire E. D., Pay G. F., Turney J., Wallis R. B., Weston M. J., White A. M., Williams L. C., Woods H. F.. The effects of two different dosage regimens of sulfinpyrazone on platelet function ex vivo and blood chemistry in man. Haemostasis 1981; 10: 153
• 40 Maseri A., Chierchia S., L' Abbate A.. Pathogenetic mechanisms underlying the clinical events associated with atherosclerotic heart disease. Circulation 1980; 62: 3 Supplementum V
• 41 Moncada S., Vane J. R.. Prostacyclin in the cardiovascular system. Advances in Prostaglandin and Thromboxane Research 1980; 6: 43
• 42 Moneada S., Korbut R.. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978; I: 1286
• 43 Moschos C. B., Lahirt K., Lyons M., Weisse A. B., Oldenwurtel H. A., Regan T. J.. Relationship of microcirculatory thrombosis to thrombus formation in the proximal coronary artery: effect of aspirin dipyridamol and thrombolysis. Amer. Heart J. 1973; 86: 61
• 44 Moschos C. B., Haider B., DeLaCruz Jr. C., Lyons M. M., Regan T. J.. Antiarrhythmic effects of aspirin during nonthrombotic coronary occlusion. Circulation 1978; 57: 681
• 45 Moschos C. B.. General Discussion. In: Proceedings of the workshop on platelet active drugs in the secondary prevention of cardiovascular events. Circulation 1980; 62: 122 Supplementum V
• 46 Moschos C. B., Escobinas A. J., Jorgen-sen O. B., Regan T. J.. Effect of sulfinpyrazone on ventricular fibrillation during acute myocardial infarction. Circulation 1981; 64: 13
• 47 Mustard J. F.. General Discussion. In: Proceedings of the workshop on platelet active drugs in the secondary prevention of cardiovascular events. Circulation 1980; 62: 47 Supplementum V
• 48 Mustard J. F.. General Discussion. I. Future directions in basic research. In: Proceedings of the workshop on platelet active drugs in the secondary prevention of cardiovascular events. Circulation 1980; 62: 126 Supplementum V
• 49 Needleman P. H., Kaley G.. Cardiac and coronary prostaglandin synthesis and function. New Engl. J. Med. 1978; 298: 1122
• 50 Niewiarowski S., Lukasiewicz H., Nath N., Tai Sha A.. Inhibition of human platelet aggregation by dipyridamole and two related compounds and its modification by acid glycoproteins of human plasma. J. Lab. Clin. Med. 1975; 86: 64
• 51 Nowak J., Kaijser L., Wennmalm A.. Cardiac synthesis of prostaglandins from arachidonic acid. Prostaglandins and Medicine 1980; 4: 205
• 52 Packham M. A., Mustard J. F.. Pharmacology of platelet affecting drugs. Circulation 1980; 62: 26 Supplementum V
• 53 Pay G. F., Wallis R. B., Zelaschi D.. The effect of sulfinpyrazone and its metabolites on platelet function in vitro and ex vivo. Haemostasis 1981; 10: 165
• 54 Pedersen A. K.. Cardiac prostacyclin release: stimulation by hypoxia and various agents. Scand. J. Haematology, Supplementum 1979; 34: 105
• 55 Pfister B., Godbillon J., Colussi D., Imhof D.. Effect of orally administered sulfinpyrazone (Anturan®) on platelet aggregation in vitro. Thrombosis Research 1980; 18: 89
• 56 Preston F. E., Whipps S., Jackson C. A., French A. J., Wyld P. J., Stoddard C. J.. Inhibition of prostacyclin and platelet thromboxane A₂ after low dose aspirin. New Engl. J. Med. 1981; 304: 76
• 57 Reichenbach D. D., Moss N. S.. Myocardial cell necrosis and sudden death in humans. Circulation 51 1975; 52: 60 Supplementum II
• 58 Roos J. C, Dunning A. J.. Clinical electrophysiological effects of sulfinpyrazone. Circulation 1980; 62: 83 Supplementum III
• 59 Schrör K., Smith III E. F., Bickerton M., Smith J. B., Nicolaou K. C., Magolda R., Lefer A. M.. Preservation of ischemic myocardium by pinane thromboxane A₂ . Amer. J. Physiol. 1980; 87
• 60 Schwartz C. J., Gerrity R. G.. Anatomical pathology of sudden unexpected cardiac death. Circulation 1975; 51: 18 52 Supplementum III
• 61 Shragge B. W., Robertson M. A., Nolan W. T., Buchanan M. R., Hirsh J.. The antiarrhythmic effects of sulfinpyrazone in the isolated rabbit heart. Circulation 1980; 62: 83 Supplementum III
• 62 Silver M. G., Hoch W., Kocsis J. J., Ingerman C. M., Smith J. B.. Arachidonic acid causes sudden death in rabbits. Science 1974; 183: 1085
• 63 Smith J. B., Araki H., Lefer A. M.. Thromboxane A₂ . prostacyclin and aspirin: effects on vascular tone and platelet aggregation. Circulation 1980; 62: 19 Supplementum V
• 64 Smythe H. A., Ogryzlo M. A., Murphey F. A., Mustard J. F.. The effect of sulfinpyrazone (Anturane) on platelet economy and blood coagulation in human. Canad. Med. Ass. J. 1965; 92: 818
• 65 Somberg J. C, Knox S.. The antiarrhythmic action of sulfinpyrazone. Circulation 1980; 62: 82 Supplementum III
• 66 Swift A., Karmazyn M., Horrobin D. F., Manku M. S., Karmali R. A., Morgan R. O., Ally A. I.. Low prostaglandin concentrations cause cardiac rhythm disturbances. Effect reversed by low levels of copper or chloroqui-ne. Prostaglandins 1978; 15: 651
• 67 Trachte G. J., Lefer A. M., Aharony D., Smith J. B.. Potent constriction of cat coronary arteries by hydro-peroxides of arachidonic acid and its blockade by antiinflammatory agents. Prostaglandins 1979; 18: 909
• 68 Verstraete M.. Les antiaggregants plaquettai-res. Rev. Prat. (Paris) 1981; 31: 509
• 69 Weksler B. B., Ley C. W., Jaffe E. A.. Stimulation of endothelial cell prostacyclin production by thrombin. trypsin, and the ionophore A 23,187. J. Clin. Invest. 1978; 62: 923
• 70 White A. M.. Mögliche Wirkungsmechanismen von Plättchenregulatoren auf der Basis experimenteller Befunde. In Abe T, Sherry S.. Ein neuer Weg zur Eindämmung des Herztodes. Huber, Bern, Stuttgart, Wien 1979; S. 43
• 71 Zimmermann R., Thiessen M., Mörl H., Weckesser G.. The paradoxical thrombogenic effect of aspirin in experimental thrombosis. Thrombosis Research 1979; 16: 843